A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy People

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00508534
First received: July 26, 2007
Last updated: May 15, 2009
Last verified: May 2009
  Purpose

This study will examine the effects of altering gastric pH in healthy volunteers on the pharmacokinetics of SB-751689 with or without food.


Condition Intervention Phase
Osteoporosis
Drug: SB-751689
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Evaluate the Effects of Repeat Dosing of Esomeprazole on the Pharmacokinetics of SB-751689 in Healthy Adult Subjects

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Cmax and AUC of SB-751689 alone or after treatment with esomeprazole, and under fasted or fed conditions [ Time Frame: over 1 week ]

Secondary Outcome Measures:
  • Adverse event report, ECGs, vital signs, laboratory test, and clinical monitoring [ Time Frame: over a week ]

Enrollment: 13
Study Start Date: July 2007
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: SB-751689
    Other Name: SB-751689
  Eligibility

Ages Eligible for Study:   21 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult males or females between the ages of 21 and 55, inclusive, will be eligible for the study. Female subjects must be of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or bilateral oophorectomy or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  • The subject has a body mass index (BMI) of 19 to 31 kg/m2 where BMI= (weight in kg)/(height in meters)2
  • Subjects must be genotyped as poor metabolizers or heterozygous extensive metabolizers for CYP2C19.
  • The subject is capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  • Genotyped homozygous extensive metabolizers for CYP2C19 (Section 6.1.1 CYP2C19 Polymorphism Genotyping).
  • Any clinically relevant abnormality identified on the screening history and physical or laboratory examination, 12-lead electrocardiogram (ECG) and/or 24 hour Holter, including QTc > or = 450 msec.
  • Positive urine drug screen at screening.
  • Positive urine test for alcohol at pre-dose.
  • Positive for HIV at screening
  • Chronic hepatitis B and C, as evidenced by positive Hepatitis B surface antigen or Hepatitis C antibody.
  • Urinary cotinine levels indicative of smoking at screening.
  • History of smoking or use of nicotine containing products within one year of the study or >10 pack-year history of smoking overall.
  • History of regular alcohol consumption exceeding 7 units/week for women and 14 units/week for men (1 unit = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.
  • History of drug abuse within 6 months of the study.
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity with 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of the current study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or nonprescription drugs including antacids, including vitamins, herbal and dietary supplements (including St. John's Wort) within 7 days or (14 days if the drug is a potential enzyme inducer or 5 half-lives, whichever is longer) prior to the first dose of study medication, unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety.
  • Consumption of red wine, grapefruit, grapefruit juice or grapefruit-containing products within 14 days prior to the first dose of study medication.
  • Donation of blood in excess of 500 mL within 56 days prior to dosing.
  • Evidence of renal, hepatic or biliary impairment
  • History of serious gastrointestinal disease
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
  • History of clinically significant cardiovascular disease.
  • History of pernicious anemia, pancreatitis, osteosarcoma or kidney stones.
  • Medical conditions which might alter bone metabolism.
  • Liver function tests (ALT, AST, GGT, alkaline phosphatase, total bilirubin) and/or parathyroid hormone (PTH) test or CPK outside the reference range at screening.
  • Males unwilling to refrain from fathering a child during the study and for 14 days following the last dose of study medication.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00508534

Locations
Singapore
GSK Investigational Site
Singapore, Singapore, 529889
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00508534     History of Changes
Other Study ID Numbers: CR9106339
Study First Received: July 26, 2007
Last Updated: May 15, 2009
Health Authority: Singapore: Health Sciences Authority
United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
pharmacokinetic study,
gastric pH

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on April 17, 2014